Wake Forest University
About 31% of weight lost by adults during GLP-1 therapy comes from lean mass
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled trial, according to findings published in Obesity.
Swallowable capsule that expands in stomach shows weight-loss, cardiometabolic benefit
SAN ANTONIO — A swallowable hydrogel capsule that expands in the stomach demonstrated significant weight-loss, cardiovascular, glycemic and quality of life benefits for patients with overweight or obesity, a speaker reported.
Many patients with cancer do not have access to clinical trials based on where they live
Most counties in the United States do not have active cancer clinical trials, according to results of an ASCO analysis.
New stroke primary prevention guideline calls for more screening of risk factors
The new guideline on primary prevention of stroke from the American Heart Association and American Stroke Association calls for more screening of risk factors such as high BP, high cholesterol and high blood glucose.
Proton therapy, IMRT comparably effective for low-, intermediate-risk prostate cancer
Photon and proton beam radiation therapies conferred similar outcomes for men with localized prostate cancer, according to results of a randomized phase 3 trial.
‘Connection to purpose’ key to clinician well-being, healthy workplace culture
Fostering a shared connection to purpose and validating the importance of institutional well-being are essential to building a healthy oncology workplace culture.
Procedure rates for women, Black men with HFrEF disparate vs. white men
Despite narrowing sex and racial procedural disparities in HF treatment, gaps persist, with lower rates of left ventricular assist device use and heart transplant among women and Black men vs. their white and male counterparts, data show.
Joint statement calls for FDA to require drug trials to include people with obesity
Five obesity advocacy organization have issued a joint statement asking the FDA to mandate that all drug approval trials include people with obesity.
After many failed trials, novel therapeutics may finally tackle high triglycerides
BOSTON — After years of failed clinical trials with agents to lower severely elevated triglycerides, emerging therapeutics hold promise for effectively addressing hypertriglyceridemia and reducing associated CV risks, a speaker reported.
SURMOUNT-3: ‘Substantial’ weight loss with tirzepatide after lifestyle intervention
DALLAS — Adults with obesity who received tirzepatide for 72 weeks following a 12-week intensive lifestyle intervention achieved a total mean weight loss greater than 24%, according to data from the SURMOUNT-3 trial.